HCW | Jotup

Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

Retrieved on:

Tuesday, March 5, 2024

Oncology, Health, Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, HCW, Drug discovery, Artificial intelligence, Conference, Pharmaceutical industry

Lantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven cancer drug discovery and development, announced that it will be presenting at a virtual conference being hosted by HCW.

Key Points:

Lantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven cancer drug discovery and development, announced that it will be presenting at a virtual conference being hosted by HCW.
The conference will be on Thursday, March 7th, and is a virtual event.
Lantern Pharma’s CEO, Mr. Panna Sharma, will be discussing and presenting via a fireside chat format at The 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference at approximately 2 pm Eastern / 11 am Pacific.
While addressing AI in drug discovery, Mr. Sharma will talk about how RADR®, Lantern’s proprietary AI platform, is transforming the cost, pace, and timeline of oncology drug development.

Caesars Republic Scottsdale, a Caesars Rewards Luxury Hotel is Now Open in Scottsdale, Arizona.

Retrieved on:

Thursday, March 7, 2024

HCW, MAC, Studio 11, CZR, Restaurant, Interior design, Scottsdale Fashion Square, Caesars Entertainment, Harrah's Entertainment, Sun, Camelback Mountain, SVN, National bank, Environment, Casino

SCOTTSDALE, Arizona, March 7, 2024 /PRNewswire-PRWeb/ -- HCW, a prominent national real estate development and property management company, is excited to announce the opening of Caesars Republic Scottsdale in Scottsdale, Arizona.

Key Points:

The highly anticipated Caesars Rewards hotel is a modern 11-story, 265-room luxury hotel.
Caesars Republic Scottsdale promises a truly unparalleled experience in the Valley of the Sun, marking the first non-gaming Caesars hotel in the United States.
The highly anticipated Caesars Rewards hotel is a modern 11-story, 265-room luxury hotel.
Integrating the Caesars Rewards loyalty network, guests can earn rewards points for their stay at Caesars Republic Scottsdale.

Caesars Republic Scottsdale Luxury Hotel Opens Hotel Reservations for April 2024

Retrieved on:

Wednesday, January 17, 2024

Camelback Mountain, CZR, HCW, MAC, Caesars Entertainment, SVN, Harrah's Entertainment, Sun, Restaurant, Scottsdale Fashion Square, Hotel

SCOTTSDALE, Ariz., Jan. 17, 2024 /PRNewswire-PRWeb/ -- HCW, a prominent national real estate development and property management company, is excited to announce the commencement of hotel reservations for Caesars Republic Scottsdale.

Key Points:

With its modern 11-story, 265-room design, Caesars Republic Scottsdale promises a truly unparalleled experience in the Valley of the Sun.
SCOTTSDALE, Ariz., Jan. 17, 2024 /PRNewswire-PRWeb/ -- HCW, a prominent national real estate development and property management company, is excited to announce the commencement of hotel reservations for Caesars Republic Scottsdale.
"The HCW team is thrilled to open reservations for Caesars Republic Scottsdale" expressed Richard Huffman, CEO & President of HCW.
Integrating the Caesars Rewards loyalty network, guests can earn rewards points for their stay at Caesars Republic Scottsdale.

HCW Announces Pre-Leasing of Tucson Landing: A Luxury Apartment Development in Tucson, AZ

Retrieved on:

Thursday, October 19, 2023

MEP, MEB, Interstate 19, Engineering, Irvington Road station, Crossland Construction Company, Interstate Highway System, HCW, Freedom, CJD, Property management, Hotel, PHOENIX

PHOENIX, Oct. 19, 2023 /PRNewswire-PRWeb/ -- HCW is proud and MEB Management Services are thrilled to announce Tucson Landing a 210-unit, gated luxury apartment community in Tucson, AZ is now pre-leasing units with move-in dates starting from December 1st. Located on 8.5 acres along Interstate 19 and Irvington Road, Tucson Landing enjoys a prime location adjacent to the vibrant Tucson Spectrum outdoor mall within the 65-acre mixed-use development, The Landing.

Key Points:

HCW is proud and MEB Management Services are thrilled to announce Tucson Landing a 210-unit, gated luxury apartment community in Tucson, AZ is now pre-leasing units with move-in dates starting from December 1st.
PHOENIX, Oct. 19, 2023 /PRNewswire-PRWeb/ -- HCW is proud and MEB Management Services are thrilled to announce Tucson Landing a 210-unit, gated luxury apartment community in Tucson, AZ is now pre-leasing units with move-in dates starting from December 1st.
Rick Huffman, HCW's President & CEO, expressed his excitement, stating, "Tucson Landing will set a new standard for luxury rental living in the Tucson community.
These exceptional amenities combine to establish Tucson Landing as the foremost luxury apartment community in the area.

Incannex Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference - September 11-13, 2023

Retrieved on:

Friday, September 8, 2023

ASX, HCW, Conference, Pharmaceutical industry, Cryptocurrency

MELBOURNE, Australia, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a pharmaceutical company developing cannabinoid pharmaceutical medicines and psychedelic therapies for unmet medical needs, is pleased to announce that it will be featured as a presenting company at the H.C. Wainwright 25th Annual Global Investment Conference - September 11-13, 2023.

Key Points:

MELBOURNE, Australia, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a pharmaceutical company developing cannabinoid pharmaceutical medicines and psychedelic therapies for unmet medical needs, is pleased to announce that it will be featured as a presenting company at the H.C. Wainwright 25th Annual Global Investment Conference - September 11-13, 2023.
Incannex will be presenting and taking one on one meetings virtually.
Mr Joel Latham, CEO and Managing Director of Incannex, will provide an overview of the Company's business during the presentation.
If you are an institutional investor and would like to listen to the Company’s presentation or request a 1x1 meeting, please click on the following link ( HCW 25th Annual Global Investment Conference Registration Link ) to register for the conference.

H. C. Wainwright Announces Annual Bitcoin Mining Panel Discussion

Retrieved on:

Monday, September 11, 2023

Banking, Cryptocurrency, Professional Services, Finance, Bitcoin, Blockchain, Research, CNBC, Panel, Lotte New York Palace Hotel, Growth, HCW, Conference, Economics

H. C. Wainwright & Co., LLC, a full-service investment bank dedicated to providing corporate finance, strategic advisory and equity research coverage to public and private companies across multiple sectors and regions, is hosting its Annual Bitcoin Mining Panel as part of the H.C. Wainwright 25th Annual Global Investment Conference at the Lotte New York Palace Hotel.

Key Points:

H. C. Wainwright & Co., LLC, a full-service investment bank dedicated to providing corporate finance, strategic advisory and equity research coverage to public and private companies across multiple sectors and regions, is hosting its Annual Bitcoin Mining Panel as part of the H.C. Wainwright 25th Annual Global Investment Conference at the Lotte New York Palace Hotel.
Prominent industry executives will discuss various headline topics including: the current Bitcoin Mining landscape, technological innovations, the upcoming halving and its impact across the industry.
Participants on the industry executive panel include:
"Our #1 Bitcoin Mining investment banking and capital markets franchise* is pleased to host this Panel and offer industry executives and institutional investors a unique insight into the significant growth opportunity that Bitcoin Mining presents,” said Craig Schwabe, Managing Director, who leads the Bitcoin Mining, cryptocurrency, blockchain and financial technology investment banking franchise at H.C. Wainwright & Co.
Virtually every public Bitcoin Mining company will be presenting their business in a group setting and hosting one-on-one meetings at this year’s conference.

LM Funding America to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Retrieved on:

Wednesday, September 6, 2023

Lotte New York Palace Hotel, HCW, Conference, LM, Cryptocurrency

TAMPA, FL, Sept. 06, 2023 (GLOBE NEWSWIRE) -- LM Funding America, Inc. (NASDAQ: LMFA) (“LM Funding” or the “Company”), a cryptocurrency mining and technology-based specialty finance company, today announced that Bruce M. Rodgers, Chairman and CEO of LM Funding America will be participating in the H.C. Wainwright (HCW) 25th Annual Global Investment Conference being held September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.

Key Points:

TAMPA, FL, Sept. 06, 2023 (GLOBE NEWSWIRE) -- LM Funding America, Inc. (NASDAQ: LMFA) (“LM Funding” or the “Company”), a cryptocurrency mining and technology-based specialty finance company, today announced that Bruce M. Rodgers, Chairman and CEO of LM Funding America will be participating in the H.C. Wainwright (HCW) 25th Annual Global Investment Conference being held September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.
LM Funding’s presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 11, 2023, at 7:00 AM Eastern Time.
A webcast of the Company’s presentation can also be accessed at https://journey.ct.events/view/0d40387d-30aa-4aeb-a670-f33b6cefa1c4 and on the investor relations section of Company’s website at https://www.lmfunding.com/investors .
Management will be participating in one-on-one meetings with qualified members of the investor community throughout the conference in New York City.

A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases

Retrieved on:

Monday, April 3, 2023

MIRAMAR, Fla., April 03, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, published a pivotal scientific paper in Aging Cell entitled, “Immunotherapeutic approach to reduce senescent cells and alleviate senescence-associated secretary phenotype in mice,” with Dr. Hing C. Wong, the Company’s Founder and CEO, as lead and corresponding author. The Company is currently evaluating one of its lead product candidates, HCW9218, a bifunctional immunotherapeutic compound, in patients with chemo-resistant/chemo-refractory advanced pancreatic cancer and solid tumors. In this publication, the Company demonstrates HCW9218 may have much broader therapeutic potential beyond cancer to other age-related diseases and conditions because of its ability to promote cell-mediated mechanisms to reduce senescent cells and alleviate the proinflammatory factors they secrete, known as senescence-associated secretory phenotype (“SASP”) factors, as shown in mice.

Key Points:

This drives aging and age-related diseases, such as diabetes, osteoporosis, fibrotic diseases, cardiovascular diseases, dementia, renal failure, sarcopenia, macular degeneration, and neurodegenerative diseases, as well as other conditions such as long-haul COVID-19.
Dr. Wong founded HCW Biologics in 2018 with the vision of discovering novel immunotherapeutics to treat age-related diseases and improve healthspan.
Dr. Wong stated, “We believe that HCW9218 has the potential to redefine the approach for treating aging conditions and age-related diseases.
These data point toward the possibility that we have created a new class of immunotherapeutics for age-related diseases that will fundamentally change the way these diseases are treated.”

New Research: Talkspace Releases Early Findings that “Text Therapy” Highly Effective for Frontline Healthcare Workers at Onset of COVID-19 Pandemic

Retrieved on:

Tuesday, February 7, 2023

In March of 2020, researchers from Talkspace and leading academic centers recruited healthcare workers (HCWs) from major hospitals across the United States who were experiencing anxiety or depression as they cared for COVID-19 patients during the initial surge.

Key Points:

In March of 2020, researchers from Talkspace and leading academic centers recruited healthcare workers (HCWs) from major hospitals across the United States who were experiencing anxiety or depression as they cared for COVID-19 patients during the initial surge.
Participants could send unlimited text messages to their therapists and would receive counseling in the form of text messages back from their respective therapists.
The population included physicians, nurses at several levels, residents in training, and a small number of nonmedical sanitation workers.
The improvements shown by HCWs translated into a large effect size that puts it on par with effect sizes reported for traditional therapy.

HCW Biologics Enters CRADA with National Cancer Institute

Retrieved on:

Thursday, December 8, 2022

MIRAMAR, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today announced that under a Cooperative Research and Development Agreement (CRADA), the National Cancer Institute (NCI) and HCW Biologics Inc. (HCW Biologics) will collaborate to perform a Phase 1b/2 clinical study to evaluate the safety and tolerability of HCW Biologics’ proprietary agent, HCW9218, in patients with advanced/metastatic pancreatic cancer.

Key Points:

MIRAMAR, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today announced that under a Cooperative Research and Development Agreement (CRADA), the National Cancer Institute (NCI) and HCW Biologics Inc. (HCW Biologics) will collaborate to perform a Phase 1b/2 clinical study to evaluate the safety and tolerability of HCW Biologics’ proprietary agent, HCW9218, in patients with advanced/metastatic pancreatic cancer.
About the Center for Cancer Research at the National Cancer Institute:
The Center for Cancer Research (CCR), NCI’s specialized internal cancer center, has a robust clinical research program, the largest at the National Institutes of Health.
Pancreatic cancer is the third leading cause of cancer death in the United States.
The invention of HCW Biologics’ two lead molecules, HCW9218 and HCW9302, was made via the TOBI™ discovery platform.